Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Forum Dermatologicum
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

Vol 7, No 3 (2021)
Review paper
Published online: 2021-09-06
Add to basket: 49.00 PLN
Get Citation

Modern treatment of scabies

Piotr K. Krajewski1, Jacek C. Szepietowski1
DOI: 10.5603/FD.a2021.0013
·
Forum Dermatologicum 2021;7(3):73-79.
Affiliations
  1. Katedra i Klinika Dermatologii, Wenerologii i Alergologii Uniwersytetu Medycznego im. Piastów Śląskich we Wrocławiu

paid access

Vol 7, No 3 (2021)
REVIEW ARTICLES
Published online: 2021-09-06

Abstract

Scabies is a common contagious skin disease caused by the mite Sarcoptes scabiei that affects all people, regardless of age or socioeconomic status. Transmission of scabies most often occurs through direct and prolonged skin contact, which usually happens between family members and sexual partners. The most common form of scabies is classic scabies, the main symptom of which is severe itching that intensifies at night. Tunnels hollowed out by female scabies are typical lesions on the patient’s skin. These changes are mainly located in the interdigital spaces, the proximal phalanges and the flexural surfaces of the wrists. The diagnosis of scabies is mainly based on the clinical picture, but in order to confirm the infestation, adult scabies, their eggs or faeces, must be found by microscopic examination. Treatment of scabies is primarily aimed at eradicating mites as well as managing subjective symptoms and minimizing the risk of transmission. In addition to the use of medicinal preparations for all household members, it is also important to wash and iron all clothes and bedding. According to the European guidelines of 2017, the treatment of scabies is based primarily on the use of topical preparations of permethrin 5% (present in Poland in the form of a cream and gel) or ivermectin used orally at a dose of 200 μg/kg body weight. Both preparations are used twice with a weekly break between doses. Both topical permethrin and ivermectin show a similar, very high cure (over 90%).

Abstract

Scabies is a common contagious skin disease caused by the mite Sarcoptes scabiei that affects all people, regardless of age or socioeconomic status. Transmission of scabies most often occurs through direct and prolonged skin contact, which usually happens between family members and sexual partners. The most common form of scabies is classic scabies, the main symptom of which is severe itching that intensifies at night. Tunnels hollowed out by female scabies are typical lesions on the patient’s skin. These changes are mainly located in the interdigital spaces, the proximal phalanges and the flexural surfaces of the wrists. The diagnosis of scabies is mainly based on the clinical picture, but in order to confirm the infestation, adult scabies, their eggs or faeces, must be found by microscopic examination. Treatment of scabies is primarily aimed at eradicating mites as well as managing subjective symptoms and minimizing the risk of transmission. In addition to the use of medicinal preparations for all household members, it is also important to wash and iron all clothes and bedding. According to the European guidelines of 2017, the treatment of scabies is based primarily on the use of topical preparations of permethrin 5% (present in Poland in the form of a cream and gel) or ivermectin used orally at a dose of 200 μg/kg body weight. Both preparations are used twice with a weekly break between doses. Both topical permethrin and ivermectin show a similar, very high cure (over 90%).

Full Text:

Add to basket: 49.00 PLN
Get Citation

Keywords

scabies; permethrin; ivermectin

About this article
Title

Modern treatment of scabies

Journal

Forum Dermatologicum

Issue

Vol 7, No 3 (2021)

Article type

Review paper

Pages

73-79

Published online

2021-09-06

Page views

5661

Article views/downloads

50

DOI

10.5603/FD.a2021.0013

Bibliographic record

Forum Dermatologicum 2021;7(3):73-79.

Keywords

scabies
permethrin
ivermectin

Authors

Piotr K. Krajewski
Jacek C. Szepietowski

References (42)
  1. Roncalli RA, Roncalli RA. The history of scabies in veterinary and human medicine from biblical to modern times. Vet Parasitol. 1987; 25(2): 193–198.
    CrossRefPubMed
  2. Fuller LC. Epidemiology of scabies. Curr Opin Infect Dis. 2013; 26(2): 123–126.
    CrossRefPubMed
  3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2163–2196.
    CrossRefPubMed
  4. Jittamala P, Monteiro W, Smit MR, et al. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis. 2015; 15(8): 960–967.
    CrossRefPubMed
  5. Heukelbach J, Feldmeier H. Scabies. The Lancet. 2006; 367(9524): 1767–1774.
    CrossRef
  6. Fimiani M, Mazzatenta C, Alessandrini C, et al. The behaviour of Sarcoptes scabiei var. hominis in human skin: an ultrastructural study. J Submicrosc Cytol Pathol. 1997; 29(1): 105–113.
    PubMed
  7. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med. 2010; 362(8): 717–725.
    CrossRefPubMed
  8. Johnston G, Sladden M. Scabies: diagnosis and treatment. BMJ. 2005; 331(7517): 619–622.
    CrossRefPubMed
  9. Arlian LG, Runyan RA, Achar S, et al. Survival and infectivity of Sarcoptes scabiei var. canis and var. hominis. J Am Acad Dermatol. 1984; 11(2 Pt 1): 210–215.
    CrossRefPubMed
  10. Bouvresse S, Chosidow O, Chosidow O. Clinical practices. Scabies. N Engl J Med. 2006; 354(16): 1718–1727.
    CrossRefPubMed
  11. Vorou R, Remoudaki HD, Maltezou HC. Nosocomial scabies. J Hosp Infect. 2007; 65(1): 9–14.
    CrossRefPubMed
  12. Chosidow O. Scabies and pediculosis. The Lancet. 2000; 355(9206): 819–826.
    CrossRef
  13. Braun-Falco O, Burgdorf WHC, Plewig G, et al. Dermatologia. T. 1. Wydawnictwo Czelej, Lublin 2017.
  14. Eshagh K, DeKlotz CMC, Friedlander SF. Infant with a papular eruption localized to the back. JAMA Pediatr. 2014; 168(4): 379–380.
    CrossRefPubMed
  15. Salomon JA, Szepietowski J. Zastosowanie permetryny w leczeniu świerzbu. Dermatologia Kliniczna. 2013; 15(3): 121–125.
  16. Czeschik JC, Huptas L, Schadendorf D, et al. Nodular scabies: hypersensitivity reaction or infection? J Dtsch Dermatol Ges. 2011; 9(10): 840–841.
    CrossRefPubMed
  17. Buczek A, Blaszak C. Stawonogi: znaczenie epidemiologiczne. Koliber, Lublin 2006.
  18. Kartono F, Lee EW, Lanum D, et al. Crusted Norwegian scabies in an adult with Langerhans cell histiocytosis: mishaps leading to systemic chemotherapy. Arch Dermatol. 2007; 143(5): 626–628.
    CrossRefPubMed
  19. Kristjansson AK, Smith MK, Gould JW, et al. Pink pigtails are a clue for the diagnosis of scabies. J Am Acad Dermatol. 2007; 57(1): 174–175.
    CrossRefPubMed
  20. Walter B, Heukelbach J, Fengler G, et al. Comparison of dermoscopy, skin scraping, and the adhesive tape test for the diagnosis of scabies in a resource-poor setting. Arch Dermatol. 2011; 147(4): 468–473.
    CrossRefPubMed
  21. Dupuy A, Dehen L, Bourrat E, et al. Accuracy of standard dermoscopy for diagnosing scabies. J Am Acad Dermatol. 2007; 56(1): 53–62.
    CrossRefPubMed
  22. Sonthalia S, Agrawal M, Bhatia J, et al. Entodermoscopy Update: A Contemporary Review on Dermoscopy of Cutaneous Infections and Infestations. Indian Dermatol Online J. 2021; 12(2): 220–236.
    CrossRefPubMed
  23. Sluzevich JC, Sheth AP, Lucky AW. Persistent eosinophilia as a presenting sign of scabies in patients with disorders of keratinization. Arch Dermatol. 2007; 143(5): 670–673.
    CrossRefPubMed
  24. Salavastru CM, Chosidow O, Boffa MJ, et al. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017; 31(8): 1248–1253.
    CrossRefPubMed
  25. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev. 2007(3): CD000320.
    CrossRefPubMed
  26. Johnstone P, Strong M. Scabies. BMJ Clin Evid. 2014: 2014.
  27. Thadanipon K, Anothaisintawee T, Rattanasiri S, et al. Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2019; 80(5): 1435–1444.
    CrossRefPubMed
  28. Ranjkesh MR, Naghili B, Goldust M, et al. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. Ann Parasitol. 2013; 59(4): 189–194.
    PubMed
  29. Ahmad HM, Abdel-Azim ES, Abdel-Aziz RT. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies. Dermatol Ther. 2016; 29(1): 58–63.
    CrossRefPubMed
  30. Chhaiya SB, Patel VJ, Dave JN, et al. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012; 78(5): 605–610.
    CrossRefPubMed
  31. Goldust M, Rezaee E. The efficacy of topical ivermectin versus malation 0.5% lotion for the treatment of scabies. J Dermatolog Treat. 2013 [Epub ahead of print].
    CrossRefPubMed
  32. Szepietowski J, Baran W. Terapia w dermatologii. PZWL Wydawnictwo Lekarskie, Warszawa 2019.
  33. Laing R, Gillan V, Devaney E. Ivermectin - Old Drug, New Tricks? Trends Parasitol. 2017; 33(6): 463–472.
    CrossRefPubMed
  34. Ashour DS. Ivermectin: From theory to clinical application. Int J Antimicrob Agents. 2019; 54(2): 134–142.
    CrossRefPubMed
  35. Rosumeck S, Nast A, Dressler C, et al. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. 2018; 4(6): CD012994–732.
    CrossRefPubMed
  36. Chiu S, Argaez C. Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines. CADTH Rapid Response Reports, Ottawa 2019.
  37. AL Ja, Amin M. Comparison the effectiveness of sulphur ointment, permethrin and oral ivermectin in treatment of scabies. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2018; 9(1): 670–676.
  38. Workowski KA, Bolan GA. Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03): 1–137.
  39. Bécourt C, Marguet C, Balguerie X, et al. Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy. Br J Dermatol. 2013; 169(4): 931–933.
    CrossRefPubMed
  40. Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J. 2005; 81(951): 7–11.
    CrossRefPubMed
  41. Zawar V, Pawar M. Liquid nitrogen cryotherapy in the treatment of chronic, unresponsive nodular scabies. J Am Acad Dermatol. 2017; 77(2): e43–e44.
    CrossRefPubMed
  42. Mittal A, Garg A, Agarwal N, et al. Treatment of nodular scabies with topical tacrolimus. Indian Dermatol Online J. 2013; 4(1): 52–53.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl